Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 28 (17), 2816-2826

Vinca Alkaloids and Analogues as Anti-Cancer Agents: Looking Back, Peering Ahead

Affiliations
Review

Vinca Alkaloids and Analogues as Anti-Cancer Agents: Looking Back, Peering Ahead

Emanuela Martino et al. Bioorg Med Chem Lett.

Abstract

Cancer still represents a "nightmare" worldwide, causing annually millions of victims. Several antiproliferative molecules are currently used as drugs market and offer a pharmaceutical opportunity for attenuating and treating tumor manifestations. In this context, natural sources have a relevant role, since they provide the 60% of currently-used anticancer agents. Among the numerous natural products, acting via different mechanisms of action, microtubule-targeting agents (MTAs) have a high therapeutic potential, since they disrupt the abnormal cancer cell growth, interfering with the continuous mitotic division. Vinca alkaloids (VAs) are the earliest developed MTAs and approved for clinical use (Vincristine, Vinblastine, Vinorelbine, Vindesine, and Vinflunine) as agents in the treatment of hematological and lymphatic neoplasms. Here, we review the state-of-art of VAs, discussing their mechanism of action and pharmacokinetic properties and highlighting their therapeutic relevance and toxicological profile. Additionally, we briefly disclosed the technological approaches faced so far to ameliorate the pharmacological properties, as well as to avoid the drug resistance. Lastly, we introduced the recent advances in the discovery of new derivatives.

Keywords: Antimitotic agents; Emerging vinblastine-related compounds; Microtubule-targeting agents; Vinca alkaloids.

Similar articles

See all similar articles

Cited by 7 PubMed Central articles

See all "Cited by" articles

MeSH terms

LinkOut - more resources

Feedback